Patents by Inventor Gerrit Jansen

Gerrit Jansen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11956489
    Abstract: In accordance with the present invention, systems and methods that allow a television broadcast facility or a headend to insert in-band messages, where the inserted message allow receivers to switch to, insert, or otherwise show addressable advertisements to its viewers.
    Type: Grant
    Filed: July 28, 2020
    Date of Patent: April 9, 2024
    Assignee: TIVO CORPORATION
    Inventors: Seth Haberman, Gerrit Niemeijer, Alex Jansen, Erik van de Pol
  • Patent number: 11956490
    Abstract: In accordance with the present invention, systems and methods that allow a television broadcast facility or a headend to insert in-band messages, where the inserted message allow receivers to switch to, insert, or otherwise show addressable advertisements to its viewers.
    Type: Grant
    Filed: December 30, 2020
    Date of Patent: April 9, 2024
    Assignee: TiVo Corporation
    Inventors: Seth Haberman, Gerrit Niemeijer, Alex Jansen, Erik van de Pol
  • Patent number: 11103562
    Abstract: Present invention relates to a composition for use in the treatment of arthritides. Alkaline phosphatase (AP), an ectophosphatase with an anti-inflammatory and barrier protecting mechanism of action shows potent anti-rheumatoid arthritis (anti-RA) efficacy in a rat model for arthritis. In this model RA was induced by subcutaneous immunization with a mixture of methylated bovine serum albumin (mBSA), CFA (complete Freund's adjuvant antigen) and CBP (custom Bordetella pertussis antigen) and intra-articular injections of mBSA. Results were comparable with those obtained for MTX, the drug reference compound for the treatment of RA. Both knee swelling over time and the number of invading macrophages were found to be reduced with AP treatment, either applied in prophylactic treatment or therapeutic treatment, and comparable to the MTX effects. AP was found effective both as prophylactic, and as therapeutic intervention.
    Type: Grant
    Filed: December 12, 2017
    Date of Patent: August 31, 2021
    Assignee: AMRIF BV
    Inventors: Rudi Brands, Willem Seinen, Carolina Frederika Maria Molthoff, Gerrit Jansen, Ronald Sake Oosting
  • Publication number: 20200121765
    Abstract: Present invention relates to a composition for use in the treatment of arthritides. Alkaline phosphatase (AP), an ectophosphatase with an anti-inflammatory and barrier protecting mechanism of action shows potent anti-rheumatoid arthritis (anti-RA) efficacy in a rat model for arthritis. In this model RA was induced by subcutaneous immunization with a mixture of methylated bovine serum albumin (mBSA), CFA (complete Freund's adjuvant antigen) and CBP (custom Bordetella pertussis antigen) and intra-articular injections of mBSA. Results were comparable with those obtained for MTX, the drug reference compound for the treatment of RA. Both knee swelling over time and the number of invading macrophages were found to be reduced with AP treatment, either applied in prophylactic treatment or therapeutic treatment, and comparable to the MTX effects. AP was found effective both as prophylactic, and as therapeutic intervention.
    Type: Application
    Filed: December 12, 2017
    Publication date: April 23, 2020
    Inventors: Rudi Brands, Willem Seinen, Carolina Frederika Maria Molthoff, Gerrit Jansen, Ronald Sake Oosting
  • Patent number: 8466111
    Abstract: A cyclopenta[g]quinazoline derivative, containing an L-Glu-?-D-Glu dipeptide group, of formula (I): wherein R1 is amino, C1-4 hydroxyalkyl, C1-4 fluoroalkyl or methoxy-C1-4-alkyl; R2 is hydrogen, C1-4 alkyl, C3-4 alkenyl, C3-4 alkynyl, C2-4 hydroxyalkyl C2-4 halogenoalkyl or C1-4 cyanoalkyl; and Ar is phenylene, thiophenediyl, thiazolediyl, pyridinediyl or pyrimidinediyl which may optionally bear one or two substituents selected from halogeno, hydroxy, amino, nitro, cyano, trifluoromethyl, C1-4 alkyl and C1-4 alkoxy, the compound (I) optionally being in the form of a pharmaceutically acceptable salt or ester; may be used for the treatment of rheumatoid arthritis or acute myeloid leukaemia.
    Type: Grant
    Filed: March 13, 2009
    Date of Patent: June 18, 2013
    Assignee: BTG International Limited
    Inventors: Gerrit Jansen, Ann Jackman
  • Publication number: 20110190211
    Abstract: A cyclopenta[g]quinazoline derivative, containing an L-Glu-?-D-Glu dipeptide group, of formula (I): wherein R1 is amino, C1-4 hydroxyalkyl, C1-4 fluoroalkyl or methoxy-C1-4-alkyl; R2 is hydrogen, C1-4 alkyl, C3-4 alkenyl, C3-4 alkynyl, C2-4 hydroxyalkyl C2-4 halogenoalkyl or C1-4 cyanoalkyl; and Ar is phenylene, thiophenediyl, thiazolediyl, pyridinediyl or pyrimidinediyl which may optionally bear one or two substituents selected from halogeno, hydroxy, amino, nitro, cyano, trifluoromethyl, C1-4 alkyl and C1-4 alkoxy, the compound (I) optionally being in the form of a pharmaceutically acceptable salt or ester; may be used for the treatment of rheumatoid arthritis or acute myeloid leukaemia.
    Type: Application
    Filed: March 13, 2009
    Publication date: August 4, 2011
    Inventors: Gerrit Jansen, Ann Jackman